Close Menu

NEW YORK – Belgian molecular diagnostics firm Biocartis reported on Thursday that its full-year 2019 revenues rose nearly 35 percent year over year, driven by a global adoption of its Idylla instrument and cartridges.

Biocartis also said that it has partnered with Bristol-Myers Squibb to register its Idylla MSI test as a companion diagnostic in China.

For the 12 months ended Dec. 31, 2019, Biocartis' revenues jumped to €37.4 million ($41.9 million) from €27.8 million in 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

UK Royal Statistical Society is organizing a working group to develop guidelines for assessing COVID-19 tests, the Guardian reports.

The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.

President Donald Trump's "good genes" comment raises eugenics concerns, CNN reports.

In PLOS this week: genetic analysis of tremor condition, analysis of a West and Central African tree used in traditional medicine, and more.